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Abstract
Background: The burgeoning field of biomedical research involving the mixture of human and animal materials
has attracted significant ethical controversy. Due to the many dimensions of potential ethical conflict involved in
this type of research, and the wide variety of research projects under discussion, it is difficult to obtain an overview
of the ethical debate. This paper attempts to remedy this by providing a systematic review of ethical reasons in
academic publications on human-animal chimera research.
Methods: We conducted a systematic review of the ethical literature concerning human-animal chimeras based on
the research question: “What ethical reasons have been given for or against conducting human-animal chimera
research, and how have these reasons been treated in the ongoing debate?” Our search extends until the end of
the year 2017, including MEDLINE, Embase, PhilPapers and EthxWeb databases, restricted to peer-reviewed journal
publications in English. Papers containing ethical reasons were analyzed, and the reasons were coded according to
whether they were endorsed, mentioned or rejected.
Results: Four hundred thirty-one articles were retrieved by our search, and 88 were ultimately included and
analyzed. Within these articles, we found 464 passages containing reasons for and against conducting human-
animal chimera research. We classified these reasons into five categories and, within these, identified 12 broad and
31 narrow reason types.
15% of the retrieved passages contained reasons in favor of conducting chimera research (Category P), while 85%
of the passages contained reasons against it. The reasons against conducting chimera research fell into four further
categories: reasons concerning the creation of a chimera (Category A), its treatment (Category B), reasons referring
to metaphysical or social issues resulting from its existence (Category C) and to potential downstream effects of
chimera research (Category D). A significant proportion of identified passages (46%) fell under Category C.
Conclusions: We hope that our results, in revealing the conceptual and argumentative structure of the debate and
highlighting some its most notable tendencies and prominent positions, will facilitate continued discussion and
provide a basis for the development of relevant policy and legislation.
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Background
Research involving the mixture of human and animal
materials has been controversial from its inception. Pro-
posed research projects, particularly geared towards the
production of human organs for transplantation in an
animal host [1–7], involving the implantation of human
brain stem cells into other animals [8–10], or aiming at
the creation of human-animal admixed embryos [11–
14], have spurred this debate, generating a wide
spectrum of arguments both for and against such re-
search in public and academic discourse. The far-
reaching nature of these controversies, involving a large
variety of factors debated over a range of different
venues, makes it particularly difficult, and important, to
obtain a general overview of the debate.
This paper provides a systematic review of ethical argu-
ments contained in academic publications on human-
animal chimera1 research. Systematic reviews involve
searching databases in a methodical and reproducible way,
retrieving literature according to predefined inclusion
criteria, and analyzing this literature in order to answer a
specific research question. Originally a tool of the social
sciences, their use was extended to medical contexts, pro-
viding comprehensive information on research findings
and clinical results in order to facilitate decision-making.
More recently, this method has been extended to philo-
sophical bioethics, taking as its focus the argument-based
literature found in this field [15, 16].
The research question underlying this systematic re-
view is: “What ethical reasons have been given for or
against conducting human-animal chimera research,
and how have these reasons been treated in the ongoing
debate?” In order to adequately answer this question, we
produced a detailed, multilayered classification system of
reasons, which elucidates the basic conceptual structure
of the debate. We provide quantitative information on
how often reasons have been endorsed, rejected, or
merely mentioned, to give a thorough account of posi-
tions, tendencies and camps within the literature. Finally,
we comment on the nature of our findings in the discus-
sion section, giving an indication of the factors that
might explain certain notable patterns in the results. By
providing structure to the debate, drawing attention to
central concerns, and uncovering certain specific fea-
tures of the current dispute, including potential argu-
mentative gaps and straw man arguments, we aim to
establish a basis for continued discussion and to facili-
tate the development of relevant policy and legislation.
Methods
Literature search and eligibility criteria
To minimize potential bias and ensure an exhaustive re-
trieval, several databases were screened, namely MED-
LINE, Embase, PhilPapers and EthxWeb (see Fig. 1).
Databases were searched up to 31 December 2017.
Database-specific controlled vocabulary and search strings
applied are summarized in Table 1. Respective search re-
sults were fused with a bibliography software (Thomson
Reuters EndNote®) and duplicate references removed. All
88 included publications are listed alphabetically in Table 2.
We restricted our search to English literature, due to the
proficiencies of the authors and the availability of sources.
We also focused exclusively on original, academic publica-
tions in international, peer-reviewed journals, excluding
reports, surveys, encyclopedia entries, handbook articles,
guidelines, opinions, editorials, reviews, monographs, an-
thologies, letters, web-posts and newspaper articles.
A publication was included only if it addressed at least
one ethical reason concerning why human-animal
chimera research should or should not be pursued.2 De-
cisions concerning whether articles should be included
were based on the publications’ abstracts, or, if these
were inconclusive, on a close reading of the full text. All
88 included publications are listed in Table 2.
Extraction and categorization of reasons
For the development of the coding system for reasons,
we followed the methodology suggested by Strech and
Sofaer (2012) [15]. To adequately mirror the ongoing
discussion and provide in-depth analysis, we distin-
guished between three stances taken regarding a reason:
 Mere mentioning of a reason (i.e., reiteration or
consideration of a reason without unequivocal
rejection or endorsement). This includes statements
such as “X constitutes a reason against chimera
research unless measures ABC are taken”, or “X does
not constitute a reason against chimera research as
long as measures ABC are taken”.
 Rejection of a reason.
 Endorsement of a reason OR development of own
reason.
1“Chimera” is the most frequently used term in discussions on this
topic, typically encompassing any creature arising from a mixture of
human and animal material, including hybrids and cybrids.
2This means that some prominent literature on chimera research was
excluded: For example, Monika Piotrowska’s “Transferring Morality to
Human-Nonhuman Chimeras” [94] was excluded due to the fact that
it does not discuss reasons for or against conducting chimera research,
but rather puts forward a potential classification system that might
allow us to better determine how to treat human-nonhuman chimeras.
By contrast, two peer commentaries on this article that do contain dis-
cussion of reasons for or against chimera research were included in
our survey [21, 29].
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We coded each reason once per publication. For instance,
if a reason was first mentioned but then ultimately rejected,
this was only counted once as a rejection. Alternatively, if a
reason was, for example, rejected multiple times within the
same paper, perhaps on different grounds, only one passage
was coded as a rejection. Note that an author may endorse
a certain reason for one type of chimera, but, in the same
article or in another publication, reject this very same rea-
son with regard to another type of chimera.
In our categorization of types of reasons, we differenti-
ated between broad types (e.g. A.2 “Human beings/human
material might be mistreated/misused”) and narrow types
(e.g. A.2.i “Human embryo protection may be neglected”,
or A.2.ii “Undue forms of human egg donation may
occur”), with each narrow type falling under one broad
type. Each broad reason type, in turn, was collected under
one of five main reason categories (see below).
The extraction and categorization of reasons unavoid-
ably involves interpretation. To produce a stable coding
Fig. 1 Flowchart documenting the retrieval of publications, the application of inclusion/exclusion criteria and further exclusions after full
text screen
Table 1 List of databases screened with respective search
strings used
Database Search stringa
MEDLINE ((((“Chimera”[Mesh])) OR (chimera)))
AND ((((((“Ethics”[Mesh])) OR (ethics))
OR (ethical)) OR (bioethics)) OR
(bioethical))
Embase (Scopus) Bioethic* OR ethic* AND chimer*
(restricted to “Articles” and “Articles
in Press”)
PhilPapers (ethic* bioeth*) (chimer*) Fuzzy
filter advanced
EthxWeb Chimer+ AND (ethic+ OR bioethic+)
restricted to journal articles
Updates via email update
on various databases
As above
aWords refer to controlled vocabulary of respective databases
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Table 2 Included and analyzed publications in alphabetical order
[17] Abelman M, O’Rourke PP, Sonntag KC (2012) Part-human animal research: the imperative to move beyond a philosophical debate. Am J Bioeth
12 (9):26–8
[18] Ankeny RA (2003) No real categories, only chimeras and illusions: the interplay between morality and science in debates over embryonic
chimeras. Am J Bioeth 3 (3):31–3
[19] Anton R (2016) On recent advances in human engineering Provocative trends in embryology, genetics, and regenerative medicine. Politics
Life Sci 35 (2):54–68
[20] Austriaco NP (2006) How to navigate boundaries: a reply to The American Journal of Bioethics. Natl Cathol Bioeth Q 6 (1):61–71
[21] Badura-Lotter G, Fangerau H (2014) Human-animal chimeras: not only cell origin matters. Am J Bioeth 14 (2):21–2
[12] Bahadur G, Iqbal M, Malik S et al. (2008) Admixed human embryos and stem cells: legislative, ethical and scientific advances. Reprod Biomed
Online 17 (Suppl 1):25–32
[22] Baylis F (2008) Animal eggs for stem cell research: a path not worth taking. Am J Bioeth 8 (12):18–32
[8] Baylis F, Fenton, A. (2007) Chimera research and stem cell therapies for human neurodegenerative disorders. Camb Q Healthc Ethics 16
(2):195–208
[23] Baylis F, Robert JS (2007) Part-human chimeras: worrying the facts, probing the ethics. Am J Bioeth 7 (5):41–5
[24] Benham B, Haber M (2008) Moral confusion and developmental essentialism in part-human hybrid research. Am J Bioeth 8 (12):42–4
[25] Bok H (2003) What’s wrong with confusion? Am J Bioeth 3 (3):25–6
[4] Bourret R, Martinez E, Vialla F et al. (2016) Human-animal chimeras: ethical issues about farming chimeric animals bearing human organs. Stem
Cell Res Ther 7 (1):87
[26] Cabrera Trujillo LY, Engel-Glatter S (2014) Human-Animal Chimera: A Neuro Driven Discussion? Comparison of Three Leading European Research
Countries. Sci Eng Ethics
[13] Camporesi S, Boniolo G (2008) Fearing a non-existing Minotaur? The ethical challenges of research on cytoplasmic hybrid embryos. J Med Ethics
34 (11):821–5
[27] Capps B (2017) Do Chimeras Have Minds? Camb Q Healthc Ethics 26 (4):577–591
[28] Castle D (2003) Hopes against hopeful monsters. Am J Bioeth 3 (3):28–30
[29] Chan S (2014) Hidden anthropocentrism and the “benefit of the doubt”: problems with the “origins” approach to moral status. Am J Bioeth 14
(2):18–20
[30] Chapman A, Hiskes AL (2008) Unscrambling the eggs: cybrid research through an Embryonic Stem Cell Research Oversight Committee (ESCRO)
lens. Am J Bioeth 8 (12):44–6
[31] Charland LC (2003) Are there answers? Am J Bioeth 3 (3):1–2
[32] Cheshire WP, Jr. (2007) The moral musings of a murine chimera. Am J Bioeth 7 (5):49–50
[33] Cohen CB (2003) Creating human-nonhuman chimeras: of mice and men. Am J Bioeth 3 (3):3–5
[34] Cooley DR (2008) Genetically Engineering Human-Animal Chimeras and Lives Worth Living. Between The Species 8:1–19
[35] Coors ME (2006) Considering chimeras: the confluence of genetic engineering and ethics. Natl Cathol Bioeth Q 6 (1):75–87
[36] de Melo-Martin I (2008) Chimeras and human dignity. Kennedy Inst Ethics J 18 (4):331–46
[37] deGrazia D (2007) Human-animal chimeras: human dignity, moral status, and species prejudice. Metaphilosophy 38 (2–3):310–329
[38] DiSilvestro R (2012) The two-essence problem that wasn’t. Am J Bioeth 12 (9):34–5
[39] Eberl JT (2007) Creating non-human persons: might it be worth the risk? Am J Bioeth 7 (5):52–4
[40] Eberl JT (2012) Ontological kinds versus biological species. Am J Bioeth 12 (9):32–4
[41] Eberl JT, Ballard RA (2008) Exercising restraint in the creation of animal-human chimeras. Am J Bioeth 8 (6):45–6
[42] Eberl JT, Ballard RA (2009) Metaphysical and ethical perspectives on creating animal-human chimeras. J Med Philos 34 (5):470–86
[43] Franklin S (2003) Drawing the line at not-fully-human: what we already know. Am J Bioeth 3 (3):25–27
[44] Gerrek ML (2008) Who really causes the lady to vanish? Am J Bioeth 8 (12):46–7
[45] Greely HT (2003) Defining chimeras...and chimeric concerns. Am J Bioeth 3 (3):17–20
[9] Greely HT, Cho MK, Hogle LF et al. (2007) Thinking about the human neuron mouse. Am J Bioeth 7 (5):27–40
[46] Greene M, Schill K, Takahashi S et al. (2005) Ethics: Moral issues of human-non-human primate neural grafting. Science 309 (5733):385–6
[47] Haber MH, Benham B (2012) Reframing the ethical issues in part-human animal research: the unbearable ontology of inexorable moral
confusion. Am J Bioeth 12 (9):17–25
[48] Heathcotte B, Robert JS (2006) The strange case of the humanzee patent quest. Natl Cathol Bioeth Q 6 (1):51–9
[49] Hermeren G (2015) Ethical considerations in chimera research. Development 142 (1):3–5
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Table 2 Included and analyzed publications in alphabetical order (Continued)
[50] Hyun I (2015) From naive pluripotency to chimeras: a new ethical challenge? Development 142 (1):6–8
[51] Hyun I (2016) What’s Wrong with Human/Nonhuman Chimera Research? PLoS Biol 14 (8):e1002535
[52] Irvine R, Degeling C, Kerridge I (2012) Uncanny animals: thinking differently about ethics and the animal-human relationship. Am J Bioeth
12 (9):30–2
[53] Johnston J, Eliot C (2003) Chimeras and “human dignity”. Am J Bioeth 3 (3):W6-w8
[14] Jones DA (2010) Is the creation of admixed embryos “an offense against human dignity”? Hum Reprod Genet Ethics 16 (1):87–114
[54] Jones DA (2012) The ethics of creating chimeras and other admixed organisms. Ethics and Medicine 28 (3):81–93
[55] Karpowicz P (2003) In defense of stem cell chimeras: a response to “Crossing species boundaries”. Am J Bioeth 3 (3):17–19
[11] Karpowicz P, Cohen CB, van der Kooy D (2004) It is ethical to transplant human stem cells into nonhuman embryos. Nat Med 10 (4):331–5
[56] Karpowicz P, Cohen CB, van der Kooy D (2005) Developing human-nonhuman chimeras in human stem cell research: ethical issues and
boundaries. Kennedy Inst Ethics J 15 (2):107–34
[57] Knoppers BMJ, Yann (2007) Our social genome? Trends Biotechnol 25 (7):284–288
[58] Kobayashi NR (2003) A scientist crossing a boundary: a step into the bioethical issues surrounding stem cell research. Am J Bioeth 3 (3):15–16
[59] Lavieri RR (2007) The ethical mouse: be not like Icarus. Am J Bioeth 7 (5):57–8
[60] Levine S, Grabel L (2017) The contribution of human/non-human animal chimeras to stem cell research. Stem Cell Res 24:128–134
[61] Masaki H, Nakauchi H (2017) Interspecies chimeras for human stem cell research. Development 144 (14):2544–2547
[62] McGee DB (2003) Moral ambiguity? Yes. Moral confusion? No. Am J Bioeth 3 (3):11–12
[63] Mirkes R (2006) Is it ethical to generate human-animal chimeras? Natl Cathol Bioeth Q 6 (1):109–30
[6] Munsie M, Hyun I, Sugarman J (2017) Ethical issues in human organoid and gastruloid research. Development 144 (6):942–945
[64] Murphy TF (2008) When is an objection to hybrid stem cell research a moral objection? Am J Bioeth 8 (12):47–9
[65] Nelson JL (2008) Respecting boundaries, disparaging values. Am J Bioeth 8 (12):33–4
[66] Palacios-Gonzalez C (2015) Ethical aspects of creating human-nonhuman chimeras capable of human gamete production and human
pregnancy. Monash Bioeth Rev. 33 (2–3):181–202
[5] Palacios-Gonzalez C (2016) The ethics of killing human/great-ape chimeras for their organs: a reply to Shaw et al. Med Health Care Philos
19 (2):215–25
[67] Palacios-Gonzalez C (2017) Chimeras intended for human gamete production: an ethical alternative? Reprod Biomed Online 35 (4):387–390
[68] Palacios-González C (2015) Human dignity and the creation of human–nonhuman chimeras. Medicine, Health Care and Philosophy 18
(4):487–499
[69] Piotrowska M (2012) Who are my parents? Why assigning moral categories to genealogical relations leads to more confusion. Am J Bioeth
12 (9):28–30
[70] Pusch AF (2015) Splices: When Science Catches Up with Science Fiction. NanoEthics 9 (1):55–73
[71] Ravelingien A, Braeckman, J., Legge, M. (2006) On the moral status of humanized chimeras and the concept of human dignity. Between
the Species 6:1–22
[72] Robert JS (2006) The science and ethics of making part-human animals in stem cell biology. Faseb j 20 (7):838–45
[73] Robert JS, Baylis F (2003) Crossing species boundaries. Am J Bioeth 3 (3):1–13
[74] Robert JS, Baylis F (2003) A response to commentators on “Crossing species boundaries”. Am J Bioeth 3 (3):W-c6
[75] Robertson JA (2003) A response to “Crossing species boundaries” by Jason Scott Robert and Francoise Baylis. Am J Bioeth 3 (3):W-c5
[76] Rollin BE (2007) Of mice and men. Am J Bioeth 7 (5):55–7
[77] Rollin BE (2007) On chimeras. Zygon 42 (3):643–648
[78] Sagoff M (2003) Transgenic chimeras. Am J Bioeth 3 (3):30–1
[10] Sagoff M (2007) Further thoughts about the human neuron mouse. Am J Bioeth 7 (5):51–2
[79] Salter B, Harvey A (2014) Creating problems in the governance of science: Bioethics and human/animal chimeras. Science and Public Policy
41 (5):685–696
[80] Saniotis A (2013) Remaking homo: Ethical issues on future human enhancement. Ethics in Science and Environmental Politics 13 (1):15–21
[81] Savulescu J (2003) Human-animal transgenesis and chimeras might be an expression of our humanity. Am J Bioeth 3 (3):22–5
[82] Savulescu J, Skene L (2008) The kingdom of genes: why genes from animals and plants will make better humans. Am J Bioeth 8 (12):35–8
[83] Schaub DJ (2006) Chimeras: from poetry to science. Natl Cathol Bioeth Q 6 (1):29–35
[84] Seyfer TL (2006) An overview of chimeras and hybrids. Natl Cathol Bioeth Q 6 (1):37–49
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system and ensure intercoder reliability we employed
the following procedure: The publications that at initial
inspection appeared to be more detailed and compre-
hensive were grouped together in a first cluster of seven
publications. Two authors (D.H. and K.K.) identified and
initially categorized text passages independently in this
subsample, then discussed whether these passages dis-
played a reason and how it should be categorized. The
result was a first version of the coding system. A second
cluster of 20 publications, which still appeared to be
relatively comprehensive, was then used to check theor-
etical saturation of the categorical spectrum, and to
revise and fine-tune the categorization of reasons. At
this point, the main categories and broad reason types
had been established; only minor adjustments within the
narrow types of reasons were subsequently necessary.
All three authors (K.K., D.H., L.W.) then checked the
extraction and categorization of reasons in a random
sample of another five publications. Our assignment of
reasons was largely consistent, which we took to demon-
strate the validity of our category system.
Within the complete set of included articles, each publi-
cation was analyzed by at least two authors. In the event of
any coding incongruities, concordance was reached
through in-depth discussion.
Results
Publication characteristics
Our literature research retrieved 431 non-duplicate ref-
erences, 88 of which were included (see Fig. 1). All arti-
cles were published between 2003 and 2017 in peer-
reviewed journals. Table 3 characterizes the disciplines
of the journals in which the articles were published.
Categories, types and frequencies of reasons
Within the 88 retrieved publications, we found 464 text
passages containing reasons. The latter fall into five main
categories, 12 broad types, and 31 narrow types of reasons.
Tables documenting the frequency of reason types for
each category can be found below. A quotation exemplify-
ing each reason type is contained in Additional file 1.
Of the five main categories, Category P (positive reasons)
contains discussion of reasons in favor of chimera research.
This category contains 15% of all identified passages (70
passages), making it the third most debated category. The
reasons within Category P were divided into four broad rea-
son types: creating chimeras might lead to advances in basic
research (P.1), produce benefits for humans (P.2), prevent
direct harm to humans or animals (P.3), or entail other
benefits (P.4). 31% of all coded passages in this category are
mentions, 7% are rejections, and 61% are endorsements
(see Table 4).
The remaining four categories contain discussions of
reasons against chimera research.
Category A (chimera creation) contains reasons pertain-
ing to the process leading to the creation of a chimera.
11% of all identified passages (53 passages) are in this cat-
egory, making it the second-least debated category. There
Table 2 Included and analyzed publications in alphabetical order (Continued)
[2] Shaw D, Dondorp W, de Wert G (2014) Using non-human primates to benefit humans: research and organ transplantation. Medicine,
Health Care and Philosophy 17 (4):573–578
[85] Shaw D, Dondorp W, Geijsen N et al. (2014) Creating human organs in chimaera pigs: an ethical source of immunocompatible organs?
J Med Ethics
[86] Siegel AW (2003) The moral insignificance of crossing species boundaries. Am J Bioeth 3 (3):33–4
[87] Streiffer R (2003) In defense of the moral relevance of species boundaries. Am J Bioeth 3 (3):37–8
[88] Streiffer R (2005) At the edge of humanity: human stem cells, chimeras, and moral status. Kennedy Inst Ethics J 15 (4):347–70
[89] Streiffer R (2010) Chimeras, moral status, and public policy: implications of the abortion debate for public policy on human/nonhuman
chimera research. J Law Med Ethics 38 (2):238–50
[90] Thompson PB (2003) Crossing species boundaries is even more controversial than you think. Am J Bioeth 3 (3):14–5
[91] Urie KA, Stanley A, Friedman JD (2003) The humane imperative: a moral opportunity. Am J Bioeth 3 (3):20–21
[92] Watt H (2007) Embryos and pseudoembryos: parthenotes, reprogrammed oocytes and headless clones Journal of Medical Ethics 33
(9):554–556
[93] Zwanziger LL (2003) Crossing perspectival chasms about species. Am J Bioeth 3 (3):9–10
Table 3 Journal disciplines for all included publications
Journal Disciplines
Bioethics 46 (52.3%)
Science/Medicine 14 (15.9%)
Medical Ethics 8 (9.1%)
Theology 7 (7.9%)
Ethics General 5 (5.7%)
Ethics of Science/Technology 3 (3.4%)
Philosophy of Medicine 2 (2.3%)
Philosophy General 1 (1.1%)
Law 1 (1.1%)
Politics and Life Sciences 1 (1.1%)
Total 88 (100%)
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are two concerns here, reflected by the two broad reason
types: the potential mistreatment of animals (A.1), and the
potential mistreatment of human beings or misuse of hu-
man material (A.2). 58% of all coded passages in this cat-
egory are mentions, 28% are rejections, and 13% are
endorsements (see Table 5).
Reasons in Category B (chimera treatment) focus on
how the chimera will be treated once it is brought into
existence, holding that either in virtue of its very exist-
ence, or owing to the conditions to which it will be sub-
jected, the chimera will not receive a level of protection
and care befitting its moral status. 23% of all coded pas-
sages (105 passages) fall in this category, making it the
second-most debated category. As with the chimera cre-
ation category, the concerns here fall into two broad rea-
son types, which differ on the moral status attributed to
the chimera: B.1 assumes that the chimera will have a
moral status akin to an animal, while B.2 imagines that a
chimera might have human analogous moral status. 33%
of all coded passages in this category are mentions, 27%
are rejections, and 40% are endorsements (see Table 6).
Category C (chimera existence) contains reasons con-
cerning potential problems resulting from the existence of
a chimera. This is the most heavily debated category, con-
taining 46% of all coded passages (215 passages). Again, it
contains two broad reason types: C.1 is concerned with
the potential metaphysical implications of a human-
animal chimera (particularly the breaking down or cross-
ing of certain boundaries), while C.2 focuses on potential
social issues (such as moral confusion or slippery slope
effects). 49% of all coded passages in this category are
mentions, 39% are rejections, and 12% are endorsements
(see Table 7).
Finally, Category D (downstream effects) is concerned
with harms that may result from the application of
chimera research, and the resources that must be invested
in it. Only 5% of all coded passages (21 passages) fall
under this category, making it the least debated group of
reasons. Once more, two broad reason types can be distin-
guished: D.1 focuses on potential harms to individual pa-
tients, from, for example, the uncritical translation of
research results or the premature transfer of material from
chimeras to humans, whereas D.2 focuses on the interests
of third parties, which might be impacted by the diversion
of research funding, or by biosafety concerns. 52% of all
coded passages in this category are mentions, 29% are re-
jections, and 19% are endorsements (see Table 8).
Discussion
The frequency of endorsements, rejections and mentions
of a reason cannot, on its own, lead us to a conclusion
about that reason’s cogency, or about the merits of the ar-
guments in which that reason is deployed. Nonetheless,
our categorization and documentation of reasons concern-
ing chimera research yields a descriptive account of the
current debate, allowing us to highlight noteworthy trends,
argumentative clusters and interesting patterns within the
discussion.
Table 4 Mentions, rejections and endorsements of positive
reasons (Category P)
Positive Reasons (Category P)
P.1: The creation of chimeras may
advance basic research
Mention [23, 35, 54, 71, 79]
Reject [8, 72]
Endorse [9, 12, 13, 17, 41, 42,
59–61, 75, 76, 81, 82]
P.2: The creation of chimeras may
produce benefits for humans
P.2.i: New therapies might be
developed on the basis of chimera
research
Mention [8, 20, 41, 43, 54, 66,
71, 79, 84]
Reject [11, 22, 23]
Endorse [2, 9, 12, 13, 17, 34, 35,
39, 42, 55, 60, 67, 72, 75, 85]
P.2.ii: Chimeras might serve as sources
of transplantable organs and tissues
Mention [5, 63]
Reject [none]
Endorse [2, 4, 34, 41, 42, 51, 60,
66, 72, 85]
P.2.iii: Chimera research might open
ways to human enhancement
Mention [80]
Reject [none]
Endorse [81]
P.3: The creation of chimeras may
prevent direct harm to humans or
animalsa
Mention [12, 23, 66]
Reject [none]
Endorse [13, 41, 42]
P.4: The creation of chimeras may
have other benefitsb
Mention [46, 80]
Reject [none]
Endorse [13]
a E.g. by helping to replace human subjects or laboratory animals in
biomedical research
b E.g. by fostering the preservation of endangered species, or by allowing
animal enhancement
Table 5 Mentions, rejections and endorsements of reasons
concerning chimera creation (Category A)
Reasons Concerning Chimera Creation (Category A)
A.1: Animals might be mistreated
A.1.i: General animal welfare
may be infringed
Mention [9, 14, 22, 26, 49, 54, 59,
65, 80, 89]
Reject [76, 79]
Endorse [37]
A.1.ii: Special protection of higher
animals such as primates may be
infringed
Mention [22, 26, 46]
Reject [2]
Endorse [37, 42]
A.2: Human beings/human material
might be mistreated/misused
A.2.i: Human embryo protection
may be neglected
Mention [12, 14, 24, 26, 44, 49, 59,
64, 65, 79, 89]
Reject [9, 66, 76]
Endorse [63, 92]
A.2.ii: Undue forms of human
egg donation may occur
Mention [12, 14, 24, 54, 65]
Reject [30, 44, 64, 66, 82]
Endorse [22]
A.2.iii: Other human biological
material may be used improperly
Mention [54, 59]
Reject [9, 66, 67, 76]
Endorse [89]
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Positive reasons (category P)
(15% of all coded passages. Distribution within: 31%
mentions, 7% rejections, 61% endorsements)
It is striking that discussions of positive reasons (Category
P) constitute a rather small fraction of all passages retrieved
(15%). Additionally, these positive reasons are mostly en-
dorsed (61%) or mentioned (31%), and only rarely rejected
(7%). Both phenomena can be accounted for.
The relatively low frequency of passages referring to
positive reasons might be explained by the fact that en-
gaging with these reasons often involves speculation con-
cerning whether certain states of affairs will obtain. In
Table 7 Mentions, rejections and endorsements of reasons
concerning chimera existence (Category C)
Reasons Concerning Chimera Existence (Category C)
C.1: Crossing human-animal species
boundaries could have detrimental
metaphysical effects
C.1.i: Existence of chimeras may
threaten human dignity
Mention [2, 9, 11, 12, 20, 22, 24, 26,
27, 48, 49, 53, 73, 74, 79, 80]
Reject [8, 34, 36, 37, 57, 60, 65–68,
71, 72, 81, 82, 85, 88]
Endorse [14, 42, 54, 56, 63, 92]
C.1.ii: Existence of chimeras may
blur species identities
Mention [9, 12, 20, 23, 24, 26, 36, 37,
41, 44, 45, 48, 53, 64, 70, 71, 74, 76,
88]
Reject [4, 11, 18, 22, 46, 47, 55, 56,
66, 73, 75, 81, 85]
Endorse [14, 17, 33, 49, 63, 80, 83, 87]
C.1.iii: Existence of chimeras may
violate moral taboosa
Mention [9, 22, 26, 37, 49, 73, 88]
Reject [11, 55, 56, 66]
Endorse [83]
C.1.iv: Existence of chimeras may
evoke instinctive repugnanceb
Mention [9, 10, 12, 14, 22, 26, 34, 54,
59, 73, 93]
Reject [13, 28, 57, 65, 66, 77, 82, 85,
88]
Endorse [84]
C.1.v: Creation of chimeras may
be unnatural
Mention [4, 9, 20, 22, 26, 37, 45, 48,
49, 73, 79, 80]
Reject [11, 13, 46, 56, 66, 81, 83, 87,
88]
Endorse [none]
C.1.vi: Creation of chimeras may
amount to playing God
Mention [2, 20, 22, 48, 73, 87, 93]
Reject [65, 82, 85, 88]
Endorse [none]
C.2: Crossing human-animal species
boundaries could have detrimental
social effects
C.2.i: Existence of chimeras may
lead to moral confusionc
Mention [8, 9, 20, 23, 26, 27, 29, 30,
33–35, 43, 48, 49, 52, 74, 75]
Reject [22, 24, 25, 28, 31, 38, 40, 47,
55, 58, 62, 65, 66, 78, 81, 82, 86, 87,
90, 91]
Endorse [17, 69, 73, 93]
C.2.ii: Existence of chimeras may
have slippery slope effectsd
Mention [12, 22, 65, 88]
Reject [13, 54, 82]
Endorse [14, 32]
C.2.iii: Creation of chimeras may
undermine public support for
scientific research
Mention [22, 30, 59, 72]
Reject [76]
Endorse [9, 14]
C.2.iv: Creation of chimeras may
result in cross-species pregnancies
Mention [6, 12, 23, 34, 35, 60, 61, 84]
Reject [4, 9, 66, 67]
Endorse [14, 54, 56]
a Suggesting that these taboos demarcate essential moral borders
b Suggesting that this repugnance hints to some relevant moral aberration
c Supposing that the existence of chimeras leads to an erosion of important
moral differences in the respective treatment of humans and animals
d Supposing that the existence of chimeras, once permitted, makes it
impossible to argue consistently against clear moral malpractices
Table 6 Mentions, rejections and endorsements of reasons
concerning chimera treatment (Category B)
Reasons Concerning Chimera Treatment (Category B)
B.1: The chimera might be violated in its
animal-analogous moral status
B.1.i: Chimera’s mere existence might be
inconsistent with animal welfare and/or
animal non-instrumentalization
Mention [9, 26]
Reject [34, 85]
Endorse [19, 70]
B.1.ii: Chimera’s further treatment might
be inconsistent with animal welfare
and/or animal non-instrumentalization
Mention [8, 54, 66]
Reject [2, 4, 67, 82, 85]
Endorse [none]
B.2: The chimera might be violated in
its human-analogous moral status
B.2.i: Chimera’s mere production might
violate human-analogous respect
Mention [36, 49]
Reject [34, 67, 68]
Endorse [14, 20, 21, 53, 63]
B.2.ii: Chimera’s mere existence might
be incompatible with human-analogous
welfare
Mention [66]
Reject [34, 68]
Endorse [53]
B.2.iii: Chimera’s developmental options
might not allow for its relevant potentiala
Mention [50, 56]
Reject [36, 68]
Endorse [26]
B.2.iv: Chimera’s early treatment might
violate human-analogous embryo
protection
Mention [22, 41, 54]
Reject [89]
Endorse [39, 42, 84]
B.2.v: Chimera’s later treatment might
be incompatible with human-analogous
rightsb
Mention [9, 26, 36, 41, 68]
Reject [4, 8, 59, 66]
Endorse [5, 10, 11, 19, 27, 37,
42, 56, 81, 88, 89, 92]
B.2.vi: Chimera might lack adequate
human-like surrounding
Mention [46]
Reject [none]
Endorse [36, 37]
B.2.vii: Chimera might be attributed
a questionable role in societyc
Mention [84]
Reject [none]
Endorse [10, 14, 81, 82]
B.2.viii Chimera might have unclear
moral status
Mention [21, 26, 60, 68, 71,
76, 77]
Reject [17, 29, 38, 52, 69]
Endorse [14, 27, 28, 32, 40, 47,
63]
B.2.ix Chimera might have human-like
capacities/characteristicsd
Mention [6, 17, 26, 27, 36, 61,
72, 79]
Reject [9, 10, 50, 51]
Endorse [11, 19, 34, 35, 89]
a E.g. when a potential for rational behavior is confined to a bodily structure
that will not support its development
b E.g. when the chimera is experimented on without adequate consent or
killed for research purposes
c E.g. when the chimera is abused as an inferior member of a slave race
d Insinuating that this possibility in itself constitutes an ethical problem
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particular, endorsing or rejecting these reasons mainly de-
pends on scientific or medical prognosis (will chimera cre-
ation lead to advances in basic research or will it not (P.1),
will chimera research foster the development of applica-
tion options or will it not (P.2)?). Additionally, it is largely
uncontroversial that these potential advances in basic and
applied research are morally desirable and they thus do
not form an attractive basis for an in-depth ethical discus-
sion. By contrast, more intricate ethical questions
concerning competition and allocation of resources are
framed negatively and are thus grouped under down-
stream effects (D.2.ii). Authors of papers retrieved in a sur-
vey of ethical arguments are likely to focus on ethically
controversial issues that call for discussion and analysis,
while, at the same time, they may not be ideally placed to
predict in a detailed manner just what benefits we might
expect to obtain from chimera research. It is therefore un-
surprising that these authors do not engage primarily with
positive reasons, focusing instead on the more ethically
controversial issues in the negative categories.
Concerning the relatively low rejection rate of positive
reasons, suggestions that chimeras might contribute to
basic research or could lead to valuable applications are
rather vague, making targeted criticism difficult. Rejec-
tions in this field would mainly have to amount to accu-
sations of “overselling”. This skepticism, however, is not
easy to substantiate. Furthermore, it would require de-
tailed predictions of benefits, which, as noted above, are
not likely to form a central focus in the ethical literature.
Negative reasons (categories A-D)
(85% of all coded passages. Distribution within: 46%
mentions, 34% rejections, 20% endorsements)
The four remaining negative categories focus on more
ethically controversial issues, require more ethical ana-
lysis, and involve, on the whole, less detailed empirical
conjecture. This is particularly the case for the categories
concerning chimera treatment (B) and chimera existence
(C). For example, suggestions that bringing a chimera into
existence might violate human-analogous respect (B.2.i)
or that the existence of chimeras might threaten human
dignity (C.1.i) requires discussion of ethical concepts (just
what do human-analogous respect and human dignity
amount to, and why would chimera research threaten
these standards?). In addition, these discussions do not ne-
cessarily have to assume that a very specific type of
chimera will exist, as, for example, any chimera with
human-associated capacities or with a sufficient amount
of human material might invoke concerns of human re-
spect and human dignity (even if the existence of these
types of chimeras remains, for the moment, rather vision-
ary). To be sure, some of these issues do involve a certain
degree of empirical conjecture (relatively specific capaci-
ties will be relevant to some reasons in the chimera treat-
ment category (B), such as the contention that certain
types of chimeras would seriously suffer (B.1.i), or that ill-
treatment will result from the chimera having a human-
like consciousness (B.2.ix)). Similarly, other arguments
rely on certain psychological or sociological postulates (for
example, reasons in the chimera existence category (C) as-
sume that there are certain social taboos that the existence
of chimeras might violate (C.1.iii), or that important psy-
chological and social barriers will be threatened by the ex-
istence of chimeras, leading to moral confusion (C.2.i)).
Even in these cases, however, there are hotly debated eth-
ical concepts and issues that require sustained discussion
to make a case that we should (or should not) view this as
a serious ethical problem (could this suffering be justified
in certain circumstances, why should a human-like con-
sciousness be avoided, is there anything wrong with violat-
ing taboos, why is moral confusion a problem?).
It should also be noted that some of the ethical issues
raised by chimera research are familiar from other bio-
ethical contexts. This is particularly true for reasons con-
cerning chimera creation (A), chimera treatment (B –
particularly B.1, where the chimera is presumed to have
animal-analogous moral status) and downstream effects
(D), which refer to common problems of animal experi-
mentation (A.1, B.1), the use of human biological material
(A.2), safety (D.1, D.2.i), and justice (D.2.ii). It is thus un-
surprising that, in a survey of academic literature, which is
inherently striving for originality and innovation, these
reasons are reiterated relatively infrequently (B.1, D), or
merely mentioned rather than discussed in a sustained
manner (A). In addition, the safety-based concerns in D.1
and D.2.i, like the positive reasons, are predicated on spe-
cific scenarios coming to pass (will it indeed be the case
that the results of chimera research pose a threat to the
individual (D.1) or to biosafety in general (D.2.i), and, if
so, how significant are the risks?). Although there is a
Table 8 Mentions, rejections and endorsements of reasons
concerning downstream effects (Category D)
Reasons Concerning Downstream Effects (Category D)
D.1: Individual medical safety might be
infringed
Mention [4, 49, 54, 66]
Reject [82, 85]
Endorse [8, 19, 35]
D.2: Third party interests might be infringed
D.2.i: Findings and substances may threaten
general biosafetya
Mention [14, 26, 27, 54,
85]
Reject [2, 72]
Endorse [89]
D.2.ii: Funding chimera research may
contradict distributive justiceb
Mention [24, 89]
Reject [13, 82]
Endorse [none]
a Particularly by spreading new diseases
b Particularly by affording more financial resources than would be warranted
on objective grounds
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more controversial ethical issue at the heart of these con-
cerns than within the category of positive reasons (which
risks would be acceptable?), this question is not an attract-
ive candidate for sustained ethical consideration, due to
the fact that it is not specific to chimera research and thus
tends to bypass the discussion of novel issues in favor of
appeals to general moral standards concerning risk-taking.
Finally, the fact that more articles are concerned with
negative reasons (A-D) than with positive reasons (P) does
not imply a negative attitude towards chimera research, as
reasons discussed might only be mentioned, or even ultim-
ately rejected rather than endorsed by the author. At the
same time, however, the fact that reasons in the negative
categories (A-D) exhibit an overall surplus of rejections
(34%) over endorsements (20%) does not indicate a positive
attitude towards chimera research either, as it is possible to
repudiate certain reasons against conducting chimera re-
search without approving of the practice overall.
Reasons concerning chimera creation (category a)
(11% of all coded passages. Distribution within: 58%
mentions, 28% rejections, 13% endorsements)
The relatively infrequent appearance of passages within
this category (11%) might be attributed to the fact that
these reasons rehash well-known arguments concerning
the treatment of animals in research (A.1) and the use of
human biological material, including human embryos
and human eggs (A.2) (see above). As such, arguments
dealing with these issues can be found in existing bio-
ethical literature, requiring only minor amendments for
application to the cases at hand. There is thus a limited
incentive for authors to engage in sustained discussion
of reasons pertaining to chimera creation. Of course, this
by no means precludes their practical relevance.
Reasons concerning chimera treatment (category B)
(23% of all coded passages. Distribution within: 33%
mentions, 27% rejections, 40% endorsements)
The chimera treatment category is composed of two broad
reason types – one based on the assumption that chimeras
will have animal-analogous moral status (B.1), while the
other proceeds from the assumption that chimeras will
have human-analogous moral status (B.2). The relatively
high proportion of endorsements (40%) compared to rejec-
tions (27%) for both broad reason types might be a result
of the fact that challenging these reasons is likely to be
based on specific assumptions about the capacities of
chimeras (for example, doubting that chimeras would ever
attain human-analogous capacities (see B.2.ix)), which, as
noted above, may not be the area of expertise of many au-
thors writing ethical papers. It is only in very few cases that
it seems possible to challenge these arguments through
questioning the moral standards to which they appeal (for
example, by arguing that a being with a certain potential is
not necessarily owed corresponding developmental options
(see B.2.iii)), but generally, the moral standards invoked are
largely uncontroversial. Thus, while pointing out problems
with chimera treatment may involve novel ethical discus-
sion (through highlighting novel dangers of maltreatment,
instrumentalization etc. in biomedical practice), the repudi-
ation of these arguments will mostly be a matter of suggest-
ing that these potential scenarios will not ultimately
materialize.
Reasons predicated on the idea that chimeras have
animal-analogous status (B.1) suffer from the familiarity of
animal ethics arguments in general, which could explain
their infrequent representation in comparison to reasons
which involve speculation that a chimera might have
human-analogous moral status (B.2). As above, this does
not preclude their importance in practice, particularly as
the notion of a chimera with human-analogous traits is
rather speculative. Furthermore, it should be noted that
concerns with animal protection are distributed between
the chimera treatment category (B, specifically B.1) and the
chimera creation category (A, specifically A.1), depending
on whether the authors are concerned with harms to ani-
mals in the chimera generation process, or to the resulting
animal-analogous chimera. Animal issues thus make up a
greater proportion of the debate than may be apparent at
first glance.
Reasons concerning chimera existence (category C)
(46% of all coded passages. Distribution within: 49%
mentions, 39% rejections, 12% endorsements)
Reasons concerning chimera existence make up a signifi-
cant proportion of all retrieved passages (46%). One ex-
planation for this, and particularly for the higher
prevalence of discussions concerning chimera existence
(C) compared to discussions concerning chimera treat-
ment (B), is that much discussion of the latter involves
scrutiny of specific types of chimeras (the origin of a chi-
mera’s cells, or its prospective capacities, etc., are likely
to be relevant factors in determining how it should be
treated). Reasons concerning chimera existence, by con-
trast, mostly deal with human-animal chimeras in gen-
eral, invoking the potential metaphysical or social
implications of these beings’ mere presence.
The overall proportion of rejections (39%) in the chimera
existence category is quite high compared to endorsements
(12%). The particularly low frequency of endorsements of
reasons C.1.iii-C.1.vi (stating that the creation of chimeras
might violate moral taboos, meet with instinctive repug-
nance, corrupt the natural order, or amount to playing
God), relative to mentions and rejections, may suggest that
discussions and refutations of these reasons are, predomin-
antly, targeted at straw men. Alternatively, these reasons
could appear, or be perceived to appear, in lay discourse,
rather than in scholarly debate.
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The fact that reason C.2.i (chimeras might generate moral
confusion) has so few endorsements and so many mentions
and rejections may be an editorial artefact. The first paper
to advance this reason was a target article in the American
Journal of Bioethics [73] and thus was accompanied by a
series of open peer commentaries, which tend to take a crit-
ical stance toward the article they address.3
Reasons concerning downstream effects (category D)
(5% of all coded passages. Distribution within: 52%
mentions, 29% rejections, 19% endorsements)
Reasons concerning downstream effects constitute the least
debated category (5%). Due to the paucity of data, reliable
trends cannot be identified. There are several possible ex-
planations for the infrequent discussion of downstream ef-
fects within the debate. First, the calculation of downstream
effects requires making concrete predictions about the re-
sults of chimera research (whether, for example, they are
likely to present threats to safety). This is compounded by
the fact that the concerns discussed in this category often
require far-reaching forecasts of consequences in the dis-
tant future, which are even more difficult to predict. The
relatively far-off nature of these potential consequences also
means that they might be viewed as less immediately ur-
gent. Finally, the safety (D.1, D.2.i) and justice-based (D.2.ii)
concerns contained in downstream effects are not specific
to chimera research, but could be invoked in any biomed-
ical context. All of these aspects might contribute to down-
stream effects being less attractive candidates for discussion.
Limitations
Although we devised the conception and methodology
of our work with close regard to its purpose and de-
mands, this study has certain limitations that need to be
critically addressed. More precisely, these limitations
concern the risks of: (1) data not being comprehensively
included in our survey; (2) results not being unani-
mously extractable from the data; (3) conclusions not
being readily inferable from the results.
Limitations of data, due to selection criteria and search
procedures
As noted above (see Methods), we restricted our review
of academic literature to English sources and to articles
in international peer-reviewed journals. The restriction
to English literature risks overlooking arguments from
other cultural spheres. However, because English has be-
come the dominant language for international bioethical
discourse, we are confident that our data accurately
reflects the scholarly debate at an international level.
The restriction to peer-reviewed journal articles might
also lead to the inadvertent exclusion of certain argu-
ments. However, the inclusion of non-peer-reviewed lit-
erature would make it difficult to consistently exclude
lay sources, feature pages, and other public opinion pos-
ition papers. In addition, reports, surveys, encyclopedia
entries, handbook articles etc. often summarize existing
debates, and thus may lead to a distortion of data
through a double-counting of reasons. The restriction to
English [95–98] and peer-reviewed journal articles [95–
97, 99, 100] is common in systematic reviews of reasons.
Additionally, it is possible that not all publications
conforming to our selection criteria were included, be-
cause they do not appear in the databases searched, or
because our search strings did not pick them up. It is
also possible that, of the articles retrieved, we failed to
identify some articles that met our inclusion criteria. We
attempted to mitigate the latter limitation by requiring
consensus concerning inclusion.
Limitations of results, concerning the attribution of text
passages to reason types
Because coding of the passages could not be based on a
simple search for keywords or catch phrases (the word
“dignity”, for example, is deployed both to express con-
cerns about the treatment of a chimera and the integrity
of the human species), reasons were identified by a close
reading and analysis of the texts. This introduces the
danger of subjectivity, which we attempted to mitigate
by coding passages independently, and eliminating dis-
parities through discussion.
Limitations of conclusions
As outlined above (see Discussion), the number of men-
tions, rejections and endorsements of specific reasons
does not allow us to draw any normative conclusions
about the quality of the arguments, but rather provides a
purely descriptive account of the current debate. Even
descriptive conclusions, however, can only be drawn
with caution. As outlined in the discussion above, the
frequencies of reason mentions, endorsements and rejec-
tions might often be explained as a function of the pecu-
liarities of academic bioethical debate. In particular, it is
thus possible that our results do not mirror the concerns
that bioethicists (even the authors included in our re-
view) would identify as the most pressing. For instance,
a bioethicist might publish a paper on a novel issue due
to its interesting implications, or to capitalize in a gap
on the debate. At the same time, however, she might
hold that the most urgent moral problems with chimera
research are the more familiar bioethical problems (such
as animal suffering or translational risk).
3It should be noted that another target article [47] focusing on moral
confusion was published in the same journal in 2012 alongside five
peer commentaries. Here, however, the results were not as skewed,
with two endorsements [17, 69], one mention [52] and two rejections
[38, 40] identified in the peer commentaries.
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Conclusion
To the best of our knowledge, this review is the first sys-
tematic review of ethical arguments concerning chimera
research. We have identified five broad categories of rea-
sons: positive reasons (P), and negative reasons pertaining
to chimera creation (A), chimera treatment (B), chimera
existence (C), and downstream effects (D). Within these
categories, we identified 12 broad and 31 narrow types of
reasons, and surveyed the frequencies of their mentions,
rejections and endorsements. We hope that the classifica-
tion into these five broad categories in particular provides
an easily accessible overview of the debate, through sup-
plying a systematic classification that reveals the disparate
nature of the concerns advanced by various authors across
different categories, as well as highlighting the connec-
tions between positions taken within the categories.4
As an enterprise in descriptive ethics, a systematic review
of reasons, as noted above, can yield no immediate norma-
tive answers concerning where this debate should move, or
which approaches are ethically superior to others. Rather,
by outlining the structure of the debate, presenting and
interpreting trends, and revealing prominent positions, we
have attempted to provide orientation in this complex de-
bate, thus facilitating future academic discussion and policy
decisions.
However, some lessons can be drawn from our results.
First, we have revealed that ethical stances towards
chimera research focus on highly diverse aspects of this
scientific endeavor, which invoke a variety of concerns in
biomedical ethics (the expected benefits of scientific ad-
vances, the ethics of using laboratory animals and human
material, the protection of higher organisms, the ontology
and sociology of interspecies relations, and the responsi-
bility for more remote research consequences). We sus-
pect that the highly fragmented nature of this debate can
undermine coherent assessment of, and ethical consensus
concerning the permissibility of, proposed chimera re-
search projects. We hope that our contribution might
begin to ameliorate this: by highlighting the different cat-
egories of ethical concern, our classification system may
help to allow ethicists and policy-makers to get on the
same page, and reduce the risk of them talking past each
other. Second, our results highlight a potentially fruitful
area of further inquiry: work exploring the connections
and interdependence of the concerns across the different
categories [101]. Ultimately, we need a unified picture of
the ethical challenges of human-animal chimera research
in order to come to a more integrated assessment of this
rapidly developing technology.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s12910-020-00465-7.
Additional file 1. Illustrative quotation for each reason type. We have
included this file to demonstrate how we assigned reasons to text
passages. It contains an exemplary passage for every reason, formulated
as endorsement, rejection or mention. This table should help to further
understand the classification system of reasons per se, but also to
illuminate how mentions demarcate from rejections and/or
endorsements.
Abbreviations
MEDLINE: Medical Literature analysis and retrieval system online (a database);
MeSH: Medical subject headings; Embase: Excerpta Medica database (a
database)
Acknowledgements
The authors thank Daniel Strech for his useful comments on methodology
and manuscript preparation and Daniel Rasch for his assistance in extracting
and compiling the data.
Authors’ contributions
K.K. conceived this study, decided upon the framework for analysis, carried
out the literature searching and analysis and drafted the manuscript. L.W.
participated in literature searching, data analysis and extensive redrafting of
the manuscript. D.H. participated in establishing the framework for analysis,
data analysis and redrafting of the manuscript. All authors have read and
approved the final version.
Funding
This project was financially supported by the German Research Foundation
(DFG) via the grant “Cluster of Excellence REBIRTH (EXC 62) – From
Regenerative Biology to Reconstructive Therapy”. The publication of this
article was funded by the Open Access fund of Leibniz University Hannover.
The funding bodies had no influence on the design of the study, the
collection, analysis and interpretation of data, or the writing of the
manuscript.
Availability of data and materials
The authors ensure full transparency of the review process. The full search
strategy is presented in Fig. 1 as well as Table 1 of the manuscript, and all
databases searched have been listed in the manuscript.
All data generated or analyzed during this study are included in this
published article (and its supplementary information files).
Ethics approval and consent to participate
Not applicable.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Author details
1CELLS – Centre for Ethics and Law in the Life Sciences, Leibniz University
Hannover, Otto-Brenner-Strasse 1, 30159 Hannover, Germany. 2Institute of
Philosophy, Leibniz University Hannover, Im Moore 21, 30167 Hannover,
Germany.
Received: 17 March 2019 Accepted: 6 March 2020
References
1. Shaw D. Creating chimeras for organs is legal in Switzerland. Bioethica
Forum. 2014;14(1):24-6.
2. Shaw D, Dondorp W, de Wert G. Using non-human primates to benefit
humans: research and organ transplantation. Med Health Care Philos. 2014;
17(4):573–8.
4It is also important to note that the debate on chimera research is
ongoing, and has particularly been fueled by recent developments in
chimera research for the purposes of organ transplantation. Because of
the end date of our systematic review, some more recent, significant
contributions to the debate have not been included [101–112].
Kwisda et al. BMC Medical Ethics           (2020) 21:24 Page 12 of 14
3. Rashid T, Kobayashi T, Nakauchi H. Revisiting the flight of Icarus: making human
organs from PSCs with large animal chimeras. Cell Stem Cell. 2014;15(4):406–9.
4. Bourret R, Martinez E, Vialla F, Giquel C, Thonnat-Marin A, De Vos J. Human-
animal chimeras: ethical issues about farming chimeric animals bearing
human organs. Stem Cell Res Ther. 2016;7(1):87.
5. Palacios-Gonzalez C. The ethics of killing human/great-ape chimeras for their
organs: a reply to Shaw et al. Med Health Care Philos. 2016;19(2):215–25.
6. Munsie M, Hyun I, Sugarman J. Ethical issues in human organoid and
gastruloid research. Development. 2017;144(6):942–5.
7. Oldani G, Peloso A, Lacotte S, Meier R, Toso C. Xenogeneic chimera-
Generated by blastocyst complementation-As a potential unlimited source
of recipient-tailored organs. Xenotransplantation. 2017;24(4). https://doi.org/
c10.1111/xen.12327.
8. Baylis F, Fenton A. Chimera research and stem cell therapies for human
neurodegenerative disorders. Camb Q Healthc Ethics. 2007;16(2):195–208.
9. Greely HT, Cho MK, Hogle LF, Satz DM. Thinking about the human neuron
mouse. Am J Bioeth. 2007;7(5):27–40.
10. Sagoff M. Further thoughts about the human neuron mouse. Am J Bioeth.
2007;7(5):51–2.
11. Karpowicz P, Cohen CB, van der Kooy D. It is ethical to transplant human
stem cells into nonhuman embryos. Nat Med. 2004;10(4):331–5.
12. Bahadur G, Iqbal M, Malik S, Sanyal A, Wafa R, Noble R. Admixed human
embryos and stem cells: legislative, ethical and scientific advances. Reprod
BioMed Online. 2008;17(Suppl 1):25–32.
13. Camporesi S, Boniolo G. Fearing a non-existing minotaur? The ethical
challenges of research on cytoplasmic hybrid embryos. J Med Ethics. 2008;
34(11):821–5.
14. Jones DA. Is the creation of admixed embryos “an offense against human
dignity”? Hum Reprod Genet Ethics. 2010;16(1):87–114.
15. Strech D, Sofaer N. How to write a systematic review of reasons. J Med
Ethics. 2012;38(2):121–6.
16. McCullough LB, Coverdale JH, Chervenak FA. Constructing a systematic
review for argument-based clinical ethics literature: the example of
concealed medications. J Med Philos. 2007;32(1):65–76.
17. Abelman M, O'Rourke PP, Sonntag KC. Part-human animal research: the
imperative to move beyond a philosophical debate. Am J Bioeth. 2012;12(9):26–8.
18. Ankeny RA. No real categories, only chimeras and illusions: the interplay
between morality and science in debates over embryonic chimeras. Am J
Bioeth. 2003;3(3):31–3.
19. Anton R. On recent advances in human engineering provocative trends in
embryology, genetics, and regenerative medicine. Polit Life Sci. 2016;35(2):54–68.
20. Austriaco NP. How to navigate boundaries: a reply to the American journal
of bioethics. Natl Cathol Bioeth Q. 2006;6(1):61–71.
21. Badura-Lotter G, Fangerau H. Human-animal chimeras: not only cell origin
matters. Am J Bioeth. 2014;14(2):21–2.
22. Baylis F. Animal eggs for stem cell research: a path not worth taking. Am J
Bioeth. 2008;8(12):18–32.
23. Baylis F, Robert JS. Part-human chimeras: worrying the facts, probing the
ethics. Am J Bioeth. 2007;7(5):41–5.
24. Benham B, Haber M. Moral confusion and developmental essentialism in
part-human hybrid research. Am J Bioeth. 2008;8(12):42–4.
25. Bok H. What's wrong with confusion? Am J Bioeth. 2003;3(3):25–6.
26. Cabrera Trujillo LY, Engel-Glatter S. Human-animal chimera: a Neuro driven
discussion? Comparison of Three Leading European Research Countries. Sci
Eng Ethics. 2015;21(3):595–617.
27. Capps B. Do chimeras have minds? Camb Q Healthc Ethics. 2017;26(4):577–91.
28. Castle D. Hopes against hopeful monsters. Am J Bioeth. 2003;3(3):28–30.
29. Chan S. Hidden anthropocentrism and the “benefit of the doubt”: problems
with the “origins” approach to moral status. Am J Bioeth. 2014;14(2):18–20.
30. Chapman A, Hiskes AL. Unscrambling the eggs: cybrid research through an
embryonic stem cell research oversight committee (ESCRO) lens. Am J
Bioeth. 2008;8(12):44–6.
31. Charland LC. Are there answers? Am J Bioeth. 2003;3(3):1–2.
32. Cheshire WP Jr. The moral musings of a murine chimera. Am J Bioeth. 2007;
7(5):49–50.
33. Cohen CB. Creating human-nonhuman chimeras: of mice and men. Am J
Bioeth. 2003;3(3):3–5.
34. Cooley DR. Genetically engineering human-animal chimeras and lives worth
living. Between Species. 2008;8:1–19.
35. Coors ME. Considering chimeras: the confluence of genetic engineering
and ethics. Natl Cathol Bioeth Q. 2006;6(1):75–87.
36. de Melo-Martin I. Chimeras and human dignity. Kennedy Inst Ethics J. 2008;
18(4):331–46.
37. deGrazia D. Human-animal chimeras: human dignity, moral status, and
species prejudice. Metaphilosophy. 2007;38(2–3):310–29.
38. DiSilvestro R. The two-essence problem that wasn't. Am J Bioeth. 2012;12(9):34–5.
39. Eberl JT. Creating non-human persons: might it be worth the risk? Am J
Bioeth. 2007;7(5):52–4.
40. Eberl JT. Ontological kinds versus biological species. Am J Bioeth. 2012;12(9):
32–4.
41. Eberl JT, Ballard RA. Exercising restraint in the creation of animal-human
chimeras. Am J Bioeth. 2008;8(6):45–6.
42. Eberl JT, Ballard RA. Metaphysical and ethical perspectives on creating
animal-human chimeras. J Med Philos. 2009;34(5):470–86.
43. Franklin S. Drawing the line at not-fully-human: what we already know. Am
J Bioeth. 2003;3(3):25–7.
44. Gerrek ML. Who really causes the lady to vanish? Am J Bioeth. 2008;8(12):
46–7.
45. Greely HT. Defining chimeras...and chimeric concerns. Am J Bioeth. 2003;
3(3):17–20.
46. Greene M, Schill K, Takahashi S, Bateman-House A, Beauchamp T, Bok H,
et al. Ethics: moral issues of human-non-human primate neural grafting.
Science. 2005;309(5733):385–6.
47. Haber MH, Benham B. Reframing the ethical issues in part-human animal
research: the unbearable ontology of inexorable moral confusion. Am J
Bioeth. 2012;12(9):17–25.
48. Heathcotte B, Robert JS. The strange case of the humanzee patent quest.
Natl Cathol Bioeth Q. 2006;6(1):51–9.
49. Hermeren G. Ethical considerations in chimera research. Development. 2015;
142(1):3–5.
50. Hyun I. From naive pluripotency to chimeras: a new ethical challenge?
Development. 2015;142(1):6–8.
51. Hyun I. What's wrong with human/nonhuman chimera research? PLoS Biol.
2016;14(8):e1002535.
52. Irvine R, Degeling C, Kerridge I. Uncanny animals: thinking differently about
ethics and the animal-human relationship. Am J Bioeth. 2012;12(9):30–2.
53. Johnston J, Eliot C. Chimeras and “human dignity”. Am J Bioeth. 2003;3(3):
W6–w8.
54. Jones DA. The ethics of creating chimeras and other admixed organisms.
Ethics Med. 2012;28(3):81–93.
55. Karpowicz P. In defense of stem cell chimeras: a response to “crossing
species boundaries”. Am J Bioeth. 2003;3(3):17–9.
56. Karpowicz P, Cohen CB, van der Kooy D. Developing human-nonhuman
chimeras in human stem cell research: ethical issues and boundaries.
Kennedy Inst Ethics J. 2005;15(2):107–34.
57. Knoppers BMJ. Yann Our social genome? Trends Biotechnol. 2007;25(7):284–8.
58. Kobayashi NR. A scientist crossing a boundary: a step into the bioethical
issues surrounding stem cell research. Am J Bioeth. 2003;3(3):15–6.
59. Lavieri RR. The ethical mouse: be not like Icarus. Am J Bioeth. 2007;7(5):57–8.
60. Levine S, Grabel L. The contribution of human/non-human animal chimeras
to stem cell research. Stem Cell Res. 2017;24:128–34.
61. Masaki H, Nakauchi H. Interspecies chimeras for human stem cell research.
Development. 2017;144(14):2544–7.
62. McGee DB. Moral ambiguity? Yes. Moral confusion? No. Am J Bioeth. 2003;
3(3):11–2.
63. Mirkes R. Is it ethical to generate human-animal chimeras? Natl Cathol
Bioeth Q. 2006;6(1):109–30.
64. Murphy TF. When is an objection to hybrid stem cell research a moral
objection? Am J Bioeth. 2008;8(12):47–9.
65. Nelson JL. Respecting boundaries, disparaging values. Am J Bioeth. 2008;
8(12):33–4.
66. Palacios-Gonzalez C. Ethical aspects of creating human-nonhuman chimeras
capable of human gamete production and human pregnancy. Monash
Bioeth Rev. 2015;33(2–3):181–202.
67. Palacios-Gonzalez C. Chimeras intended for human gamete production: an
ethical alternative? Reprod BioMed Online. 2017;35(4):387–90.
68. Palacios-González C. Human dignity and the creation of human–nonhuman
chimeras. Med Health Care Philos. 2015;18(4):487–99.
69. Piotrowska M. Who are my parents? Why assigning moral categories to
genealogical relations leads to more confusion. Am J Bioeth. 2012;12(9):28–30.
70. Pusch AF. Splices: when science catches up with science fiction. NanoEthics.
2015;9(1):55–73.
Kwisda et al. BMC Medical Ethics           (2020) 21:24 Page 13 of 14
71. Ravelingien A, Braeckman J, Legge M. On the moral status of humanized
chimeras and the concept of human dignity. Between Species. 2006;6:1–22.
72. Robert JS. The science and ethics of making part-human animals in stem
cell biology. FASEB J. 2006;20(7):838–45.
73. Robert JS, Baylis F. Crossing species boundaries. Am J Bioeth. 2003;3(3):1–13.
74. Robert JS, Baylis F. A response to commentators on “Crossing species
boundaries”. Am J Bioeth. 2003;3(3):W-c6.
75. Robertson JA. A response to “Crossing species boundaries” by Jason Scott
Robert and Francoise Baylis. Am J Bioeth. 2003;3(3):W-c5.
76. Rollin BE. Of mice and men. Am J Bioeth. 2007;7(5):55–7.
77. Rollin BE. On chimeras. Zygon. 2007;42(3):643–8.
78. Sagoff M. Transgenic chimeras. Am J Bioeth. 2003;3(3):30–1.
79. Salter B, Harvey A. Creating problems in the governance of science:
bioethics and human/animal chimeras. Sci Public Policy. 2014;41(5):685–96.
80. Saniotis A. Remaking homo: ethical issues on future human enhancement.
Ethics Sci Environ Polit. 2013;13(1):15–21.
81. Savulescu J. Human-animal transgenesis and chimeras might be an
expression of our humanity. Am J Bioeth. 2003;3(3):22–5.
82. Savulescu J, Skene L. The kingdom of genes: why genes from animals and
plants will make better humans. Am J Bioeth. 2008;8(12):35–8.
83. Schaub DJ. Chimeras: from poetry to science. Natl Cathol Bioeth Q. 2006;
6(1):29–35.
84. Seyfer TL. An overview of chimeras and hybrids. Natl Cathol Bioeth Q. 2006;
6(1):37–49.
85. Shaw D, Dondorp W, Geijsen N, de Wert G. Creating human organs in
chimaera pigs: an ethical source of immunocompatible organs? J Med
Ethics. 2015;41(12):970–4.
86. Siegel AW. The moral insignificance of crossing species boundaries. Am J
Bioeth. 2003;3(3):33–4.
87. Streiffer R. In defense of the moral relevance of species boundaries. Am J
Bioeth. 2003;3(3):37–8.
88. Streiffer R. At the edge of humanity: human stem cells, chimeras, and moral
status. Kennedy Inst Ethics J. 2005;15(4):347–70.
89. Streiffer R. Chimeras, moral status, and public policy: implications of the
abortion debate for public policy on human/nonhuman chimera research. J
Law Med Ethics. 2010;38(2):238–50.
90. Thompson PB. Crossing species boundaries is even more controversial than
you think. Am J Bioeth. 2003;3(3):14–5.
91. Urie KA, Stanley A, Friedman JD. The humane imperative: a moral
opportunity. Am J Bioeth. 2003;3(3):20–1.
92. Watt H. Embryos and pseudoembryos: parthenotes, reprogrammed oocytes
and headless clones. J Med Ethics. 2007;33(9):554–6.
93. Zwanziger LL. Crossing perspectival chasms about species. Am J Bioeth.
2003;3(3):9–10.
94. Piotrowska M. Transferring morality to human-nonhuman chimeras. Am J
Bioeth. 2014;14(2):4–12.
95. van Dijke I, Bosch L, Bredenoord AL, Cornel M, Repping S, Hendriks S. The
ethics of clinical applications of germline genome modification: a
systematic review of reasons. Hum Reprod. 2018;33(9):1777–96.
96. de Graeff N, Jongsma KR, Johnston J, Hartley S, Bredenoord AL. The ethics
of genome editing in non-human animals: a systematic review of reasons
reported in the academic literature. Philos Trans R Soc Lond Ser B Biol Sci.
2019;374(1772):20180106.
97. Kars MC, van Thiel GJ, van der Graaf R, Moors M, de Graeff A, van Delden JJ.
A systematic review of reasons for gatekeeping in palliative care research.
Palliat Med. 2016;30(6):533–48.
98. Abraham NS, Young JM, Solomon MJ. A systematic review of reasons for
nonentry of eligible patients into surgical randomized controlled trials.
Surgery. 2006;139(4):469–83.
99. Fleming V, Frith L, Luyben A, Ramsayer B. Conscientious objection to
participation in abortion by midwives and nurses: a systematic review of
reasons. BMC Med Ethics. 2018;19(1):31.
100. Song F, Loke Y, Hooper L. Why are medical and health-related studies not
being published? A systematic review of reasons given by investigators.
PLoS One. 2014;9(10):e110418.
101. Hubner D. Human-animal chimeras and hybrids: an ethical paradox behind
moral confusion? J Med Philos. 2018;43(2):187–210.
102. Farahany NA, Greely HT, Hyman S, Koch C, Grady C, Pasca SP, et al. The
ethics of experimenting with human brain tissue. Nature. 2018;556(7702):
429–32.
103. Koplin JJ. Human-animal chimeras: the moral insignificance of uniquely
human capacities. Hast Cent Rep. 2019;49(5):23–32.
104. Hyun I. Ethical considerations for human-animal neurological chimera
research: mouse models and beyond. EMBO J. 2019;38(21):e103331.
105. Chen HI, Song H, Ming GL. Applications of human brain Organoids to
clinical problems. Dev Dyn. 2019;248(1):53–64.
106. De Los AA, Hyun I, Latham SR, Elsworth JD, Redmond DE Jr. Human-
monkey chimeras for modeling human disease: opportunities and
challenges. Methods Mol Biol. 2019;2005:221–31.
107. Counihan D. Neurological chimeras and the moral staircase. Methods Mol
Biol. 2019;2005:195–203.
108. Mann SP, Sun R, Hermeren G. Ethical considerations in crossing the
Xenobarrier. Methods Mol Biol. 2019;2005:175–93.
109. Hyun I. Ethical standards for chimera research oversight. Methods Mol Biol.
2019;2005:165–71.
110. Porsdam Mann S, Sun R, Hermeren G. A framework for the ethical
assessment of chimeric animal research involving human neural tissue. BMC
Med Ethics. 2019;20(1):10.
111. Casal P, Williams A. Human iPSC-Chimera Xenotransplantation and the Non-
Identity Problem. J Clin Med. 2019;8(1):95.
112. Koplin J, Wilkinson D. Moral uncertainty and the farming of human-pig
chimeras. J Med Ethics. 2019;45(7):440–6.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Kwisda et al. BMC Medical Ethics           (2020) 21:24 Page 14 of 14
